C80.0

Disseminated malignant neoplasm, unspecified

Disseminated malignant neoplasm, unspecified (C80.0) is a clinical designation used in oncology when malignant cells have spread extensively throughout multiple systems or organs of the body, often referred to as carcinomatosis, but the site of the primary tumor remains unidentified or is not documented. This classification is typically reserved for advanced-stage disease where metastases are found in various anatomical locations (such as the lungs, liver, bones, or peritoneum) without a clear origin. Clinically, this is often categorized under Cancer of Unknown Primary (CUP). The diagnosis implies that a thorough investigation has either not been completed or has failed to reveal the primary source, which often leads to complex treatment planning based on the most likely cellular morphology and distribution of the disease. The prognosis for disseminated malignancy of unspecified origin is generally poor, as it represents highly aggressive and widespread disease at the time of clinical presentation.

Clinical Symptoms

  • Profound unintentional weight loss and cachexia
  • Generalized persistent fatigue and malaise
  • Widespread bone pain or localized skeletal tenderness
  • Multiple site lymphadenopathy
  • Abdominal distension due to malignant ascites
  • Dyspnea or persistent cough from multi-focal lung involvement
  • Jaundice or hepatomegaly
  • Anorexia and early satiety
  • Night sweats
  • Cognitive changes or neurological deficits if brain metastases are present

Common Causes

  • Advanced metastatic progression of an occult primary tumor
  • Highly aggressive undifferentiated malignancy with rapid systemic spread
  • Biological properties of Cancer of Unknown Primary (CUP) showing early dissemination
  • Late-stage clinical presentation where the primary tumor has regressed or is obscured by metastases
  • Genetic mutations favoring epithelial-to-mesenchymal transition and rapid multi-organ colonization

Documentation & Coding Tips

Distinguish between disseminated disease and site-unspecified malignancy.

Example: Assessment: 68-year-old male with radiographic evidence of carcinomatosis involving the peritoneal cavity, hepatic parenchyma, and pulmonary nodules. Primary site remains occult despite extensive workup. Diagnosis: Disseminated malignant neoplasm, unspecified (C80.0). Management: High complexity decision making due to advanced systemic involvement and need for palliative chemotherapy initiation. HCC Category 8 (Metastatic Cancer) captured for risk adjustment.

Billing Focus: Documentation must specify the widespread nature of the disease to support C80.0 over C80.1. Inclusion of multiple organ systems (peritoneum, liver, lung) supports the disseminated descriptor.

Explicitly state when the primary site is unknown or occult despite diagnostic efforts.

Example: History of Present Illness: Patient presents with unintentional weight loss of 30 lbs and generalized abdominal pain. PET/CT reveals hypermetabolic activity throughout the axial skeleton and multiple visceral sites. Biopsy of supraclavicular node confirms metastatic adenocarcinoma, but primary source is not identifiable after mammography, colonoscopy, and CT imaging. Assessment: Malignant carcinomatosis, primary unknown (C80.0). Plan: Referral to Medical Oncology for systemic therapy.

Billing Focus: The documentation of exhaustive but unsuccessful diagnostic efforts for the primary site justifies the use of an unspecified code as the principal diagnosis.

Document clinical manifestations such as malignant ascites or pleural effusion separately when relevant.

Example: Assessment: Patient with disseminated malignant neoplasm (C80.0) currently presenting with significant respiratory distress due to malignant pleural effusion (J91.0). Laterality: Right-sided. Status: Acute on chronic. Risk: High risk of complications from thoracentesis due to baseline cachexia and advanced stage. Billing: J91.0 is coded as a secondary condition to C80.0 to specify the manifestation.

Billing Focus: Specifying manifestations like pleural effusion or ascites adds clinical depth and supports the use of additional CPT codes for procedures like thoracentesis.

Use ECOG or Karnofsky Performance Status to support medical necessity and complexity.

Example: Physical Exam: Cachectic appearance, ECOG Performance Status 3 (capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours). Assessment: Disseminated malignancy (C80.0) with significant functional decline. Discussion: High-level MDM regarding transition to hospice vs. salvage chemotherapy. Billing: Supports 99215 based on high complexity and high risk of morbidity/mortality.

Billing Focus: Functional status documentation provides evidence for the medical necessity of higher-level E/M codes (99215) and supports the severity of the primary diagnosis.

Specify the goals of care, especially if the encounter focus is palliative or end-of-life management.

Example: Assessment: Advanced disseminated malignant neoplasm, unspecified (C80.0). Encounter for palliative care (Z51.5) to manage intractable pain and nausea. Risk Adjustment: Patient remains in HCC 8 for active metastatic disease despite the palliative focus of the current encounter. Billing: Principal diagnosis remains C80.0 with Z51.5 as secondary.

Billing Focus: Defining the encounter as palliative (Z51.5) while maintaining the malignancy as the underlying cause ensures proper tracking of oncology-related services.

Relevant CPT Codes

Related Diagnoses

Hierarchy